» Articles » PMID: 29257257

Profiles of Differentially Expressed Genes and Overexpression of NEBL Indicates a Positive Prognosis in Patients with Colorectal Cancer

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2017 Dec 20
PMID 29257257
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The present study aimed to identify differentially expressed genes (DEGs) in colorectal cancer (CRC) and provide novel prognostic biomarkers for CRC. The microarray dataset GSE41258 was used to screen DEGs of CRC. Subsequently, a protein‑protein interaction network of DEGs and Gene Ontology analysis were performed to identify hub genes and associated biological processes. Nebulette (NEBL) and complement C1q like 1 (C1QL1) were validated using reverse transcription‑quantitative polymerase chain reaction in patients with CRC. Survival analysis was performed for the two hub genes. GSE41258 dataset included 182 CRC samples and 54 normal tissues. A total of 759 DEGs, including 279 upregulated and 480 downregulated were screened between both groups. NEBL and C1QL1 were identified as the two hub genes and upregulated genes involved in various biological processes, including 'regulation of biological quality' and 'response to stimulus', respectively. Additionally, the overexpression of NEBL and C1QL1 in experimental validation was consistent with the aforementioned bioinformatics analysis results. Survival analysis suggested that overexpressed NEBL in patients with CRC was associated with a positive prognosis for overall survival. In conclusion, CRC was associated with a large group of DEGs. From the upregulated genes, overexpressed NEBL in patients CRC indicated a positive prognosis for overall survival and may be used as a prognostic biomarker for patients with CRC.

Citing Articles

Mapping and targeting of C1ql1-expressing cells in the mouse.

Moghimyfiroozabad S, Paul M, Sigoillot S, Selimi F Sci Rep. 2023; 13(1):17563.

PMID: 37845276 PMC: 10579299. DOI: 10.1038/s41598-023-42924-2.


A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.

Liu Z, Liu H, Wang Y, Li Z BMC Gastroenterol. 2022; 22(1):435.

PMID: 36241983 PMC: 9564244. DOI: 10.1186/s12876-022-02510-8.


NEBL and AKT1 maybe new targets to eliminate the colorectal cancer cells resistance to oncolytic effect of vesicular stomatitis virus M-protein.

Mamizadeh Z, Kalani M, Parsania M, Mehdi Soltan Dallal M, Moradi A Mol Ther Oncolytics. 2022; 23:593-601.

PMID: 34977336 PMC: 8666707. DOI: 10.1016/j.omto.2021.11.013.


LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer.

Yang R, Liao Z, Cai Y, Kong J Exp Ther Med. 2018; 16(6):5215-5223.

PMID: 30542477 PMC: 6257611. DOI: 10.3892/etm.2018.6836.


Nebulette Expression Is Associated with Lymph Node Metastasis in Patients with Colorectal Cancer.

Hosseini S, Mahjoubi F, Majidzadeh T, Khaje-Hosseini F, Haghipanah M Middle East J Dig Dis. 2018; 10(3):174-179.

PMID: 30186581 PMC: 6119834. DOI: 10.15171/mejdd.2018.107.

References
1.
Ahmed F . miRNA as markers for the diagnostic screening of colon cancer. Expert Rev Anticancer Ther. 2014; 14(4):463-85. DOI: 10.1586/14737140.2014.869479. View

2.
Louis P, Hold G, Flint H . The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12(10):661-72. DOI: 10.1038/nrmicro3344. View

3.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

4.
Snezhkina A, Krasnov G, Zaretsky A, Zhavoronkov A, Nyushko K, Moskalev A . Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics. 2017; 17(Suppl 14):1011. PMC: 5249009. DOI: 10.1186/s12864-016-3351-5. View

5.
Grady W, Carethers J . Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008; 135(4):1079-99. PMC: 2866182. DOI: 10.1053/j.gastro.2008.07.076. View